Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
Journal article published in 2017 by
R. S. Finn,
A. X. Zhu,
J. Knox,
A. L. Cheng,
A. B. Siegel,
M. Kudo,
Stephen Lam Chan 
,
O. Bautista
,
O. Bautista
